Filtered By:
Source: Diabetes, Obesity and Metabolism
Condition: Heart Attack

This page shows you your search results in order of date.

Order by Relevance | Date

Total 60 results found since Jan 2013.

The Impact of Metformin Use on the Cardiovascular Effects of DPP ‐4 Inhibitors: an Analysis of Medicare Claims Data 2007‐2015
ConclusionsIncidence rate differences in multiple cardiovascular outcomes appeared more favorable when DPP ‐4i initiation occurred in the presence of metformin, suggesting a possible interaction between DPP‐4i and metformin.This article is protected by copyright. All rights reserved.
Source: Diabetes, Obesity and Metabolism - November 20, 2018 Category: Endocrinology Authors: Matthew J. Crowley, Mugdha Gokhale, Virginia Pate, Til St ürmer, John B. Buse Tags: ORIGINAL ARTICLE Source Type: research

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2 ‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - April 17, 2018 Category: Endocrinology Authors: Mikhail Kosiborod MD , K åre I. Birkeland MD , Matthew A. Cavender MD , Alex Z. Fu PhD , John P. Wilding MD , Kamlesh Khunti MD , Reinhard W. Holl MD , Anna Norhammar MD , Marit E. Jørgensen MD , Eric T. Wittbrodt Ph Source Type: research

Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow ‐Up: A Subgroup Analysis of High‐Risk ACCORDION Trial Participants
Abstract Although guidelines recommend strict blood pressure (BP) control in patients with type 2 diabetes mellitus (T2DM) and elevated cardiovascular risk, the long‐term effects of this approach are unknown. We investigated the effect of intensive BP control on clinical outcomes in patients with T2DM over 9 years of follow‐up. We included ACCORD BP participants in the standard glucose control arm who had established cardiovascular disease, chronic kidney disease, age ≥75 years or 10‐year coronary heart risk ≥15%. Participants were randomized to either intensive (systolic BP <120 mm Hg) or standard (systolic B...
Source: Diabetes, Obesity and Metabolism - February 9, 2018 Category: Endocrinology Authors: Leo F. Buckley, Dave L. Dixon, George F. Wohlford, Dayanjan S. Wijesinghe, William L. Baker, Benjamin W. Van Tassell Tags: BRIEF REPORT Source Type: research

Have we really demonstrated the cardiovascular safety of anti ‐hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes
A primary goal of the treatment of type 2 mellitus is the prevention of morbidity and mortality associated with cardiovascular disease; however, anti‐hyperglycaemic drugs have the capacity to cause deleterious effects on the circulation, a risk that is not adequately reflected by the endpoints selected for emphasis in large‐scale clinical trials that are designed to evaluate cardiovascular safety. The primary endpoint of the large‐scale studies mandated by regulatory authorities focuses only on 3 to 4 events that depict only a limited view of the circulatory system. One of the most serious adverse effects of many glu...
Source: Diabetes, Obesity and Metabolism - February 4, 2018 Category: Endocrinology Authors: Milton Packer Tags: REVIEW ARTICLE Source Type: research

Plasma proprotein ‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
ConclusionsWe found that PCSK9 was inconsistently associated with CV events in populations with type 2 diabetes. The association may depend on the level of CV risk and the background treatment.
Source: Diabetes, Obesity and Metabolism - January 14, 2018 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, Philippe Gabriel Steg, Louis Potier, Youmna Ghaleb, Sandy Elbitar, Stephanie Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Tags: ORIGINAL ARTICLE Source Type: research

Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes
Abstract A primary goal of the treatment of type 2 mellitus is the prevention of morbidity and mortality due to cardiovascular disease. However, antihyperglycemic drugs have the capacity to cause deleterious effects on the circulation, a risk that is not adequately reflected by the endpoints selected for emphasis in large‐scale clinical trials that are designed to evaluate cardiovascular safety. The primary endpoint of the large‐scale studies mandated by regulatory authorities focuses only on 3‐4 events that depict only a limited view of the circulatory system. One of the most serious adverse effects of many glucose...
Source: Diabetes, Obesity and Metabolism - January 5, 2018 Category: Endocrinology Authors: Milton Packer Tags: REVIEW ARTICLE Source Type: research

Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes
ConclusionsPCSK9 is inconsistently associated with CV events in populations with T2DM. The association may depend on the level of CV risk and the background treatment
Source: Diabetes, Obesity and Metabolism - December 5, 2017 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, P. Gabriel Steg, Louis Potier, Youmna Ghaleb, S El Bitar, S Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Hadjadj, Catheri Tags: ORIGINAL ARTICLE Source Type: research

High ‐sensitivity C‐reactive protein, low‐density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial
ConclusionsLevels of hsCRP were associated with recurrent cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome, and this association appears to be independent of and additive to the achieved LDL‐C level.
Source: Diabetes, Obesity and Metabolism - November 21, 2017 Category: Endocrinology Authors: You ‐Cheol Hwang, David A. Morrow, Christopher P. Cannon, Yuyin Liu, Richard Bergenstal, Simon Heller, Cyrus Mehta, William Cushman, George L. Bakris, Faiez Zannad, William B. White Tags: ORIGINAL ARTICLE Source Type: research

High ‐sensitivity C‐reactive Protein, Low‐Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial
ConclusionsLevels of hsCRP were associated with recurrent cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome, and this association appears to be independent of and additive to the achieved LDL‐C level.Clinical trials registration number: NCT00968708
Source: Diabetes, Obesity and Metabolism - October 24, 2017 Category: Endocrinology Authors: You ‐Cheol Hwang, David A. Morrow, Christopher P. Cannon, Yuyin Liu, Richard Bergenstal, Simon Heller, Cyrus Mehta, William Cushman, George L Bakris, Faiez Zannad, William B White Tags: ORIGINAL ARTICLE Source Type: research

Influence of Metabolic Syndrome and Race on the Relationship between Intensive Blood Pressure Control and Cardiovascular Outcomes in the SPRINT Cohort
ConclusionsIn this analysis the CV benefit of intensive SBP control did not differ among subjects by baseline MetS status, regardless of race/ethnicity.
Source: Diabetes, Obesity and Metabolism - October 12, 2017 Category: Endocrinology Authors: Kathleen Dungan, Timothy E. Craven, Kyaw Soe, Jackson T. Wright, Jan Basile, William E. Haley, Nancy R. Kressin, Uzma Rani, Leonardo Tamariz, Jeff Whittle, Alan Wiggers, Kwame Osei Tags: ORIGINAL ARTICLE Source Type: research

Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials
The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time‐to‐event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial. With liraglutide 3.0 mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person‐...
Source: Diabetes, Obesity and Metabolism - September 26, 2017 Category: Endocrinology Authors: MJ Davies, LJ Aronne, ID Caterson, AB Thomsen, PB Jacobsen, SP Marso, Tags: BRIEF REPORT Source Type: research

Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Insulin Resistance and Cardiovascular Outcomes in the ORIGIN Trial
ConclusionsInsulin resistance may not promote cardiovascular outcomes in people with dysglycemia.
Source: Diabetes, Obesity and Metabolism - September 1, 2017 Category: Endocrinology Authors: Hertzel C. Gerstein, Ele Ferrannini, Matthew C. Riddle, Salim Yusuf, Tags: ORIGINAL ARTICLE Source Type: research

Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Association of glucagon ‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system
Conclusions GLP‐1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
Source: Diabetes, Obesity and Metabolism - July 5, 2017 Category: Endocrinology Authors: Robert S. Zimmerman, Todd M. Hobbs, Brian J. Wells, Sheldon X. Kong, Michael W. Kattan, Jon Bouchard, Kevin M. Chagin, Changhong Yu, Brian Sakurada, Alex Milinovich, Wayne Weng, Janine M. Bauman, Kevin M. Pantalone Tags: ORIGINAL ARTICLE Source Type: research